Fig. 3: Relative associations of plasma biomarkers with continuous tau-PET measures in the validation cohort demonstrate most of the differences in tau-PET that are attributed to plasma eMTBR-tau243.
From: Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease
Forest plots display standardized β (colored dots) (βSTD), representing effect size to compare the relative importance of each biomarker, along with 95% CIs (black lines) from a multivariate model including all three plasma biomarkers as predictors. a–c, Analyses shown for tau-PET-positive individuals (a, n = 172), Aβ-positive individuals (b, n = 436) and all participants (c, n = 649). Outcomes are listed on the left. Models also included age and sex as covariates. Vertical dashed lines show 0. Asterisks represent significant effect (P < 0.05) for each biomarker and model. Aβ status was assessed using CSF Aβ42/40 or Aβ-PET and tau status using global tau-PET (SUVR > 1.22). All tests were two sided. Specific P values can be found in Supplementary Table 5. interm., intermediate.
